China’s Tigermed Acquires 70% Stake in Frontage Labs of US

Hangzhou Tigermed, a clinical-stage CRO, completed its $50 million acquisition of a 70% stake in Frontage Labs, following regulatory approval. Frontage, which is headquartered in Pennsylvania and has a lab in Shanghai’s Zhangjiang Hi-Tech Park, is a complementary fit for Tigermed because it offers bioanalysis, preclinical studies, early-stage clinical studies and product development services, as well as a well-established presence in the US. The acquisition was originally announced in May 2014. More details.... Stock Symbol: (SHE: 300347) Share this with colleagues: // //